What Are the Next Steps for Iclaprim?

David Huang, PhD, MD, chief medical officer at Motif Bio, explains what the next steps are for iclaprim, an antibiotic developed to treat patients with acute bacterial skin and skin structure infections. Dr. Huang shares that if the results of REVIVE 2 are favorable, then he and his team will submit a new drug application to the US Food and Drug Administration in the first half of next year.